Nangaku相关文献与解析，生知库 | 链接生命科学的每一步

Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database

按年龄、肾功能和体重指数分层的抗糖尿病药物使用趋势演变：来自全国索赔数据库的启示

Aoyama, Kazuki; Okada, Akira; Kaneko, Hidehiro; Azegami, Tatsuhiko; Suzuki, Yuta; Meguro, Shu; Fujiu, Katsuhito; Takeda, Norifumi; Morita, Hiroyuki; Node, Koichi; Yamauchi, Toshimasa; Nangaku, Masaomi; Takeda, Norihiko; Yasunaga, Hideo; Hayashi, Kaori

糖尿病

代谢

发表日期：2026

文献求助收藏

Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD Study)

日本肾脏协会-培马贝特干预治疗慢性肾脏病患者研究（JKAPI-CKD 研究）的设计

期刊:Clinical Kidney Journal

影响因子:4.6

doi:10.1093/ckj/sfag053

Kinguchi, Sho; Tamura, Kouichi; Yano, Yuichiro; Nangaku, Masaomi; Isaka, Yoshitaka; Maruyama, Shoichi; Kanegae, Hiroshi; Heerspink, Hiddo Lambers; Nakagawa, Naoki; Nishio, Saori; Asahi, Koichi; Yamagata, Kunihiro; Fukui, Akira; Okada, Hirokazu; Narita, Ichiei; Tsuruya, Kazuhiko; Wada, Jun; Terada, Yoshio; Mukoyama, Masashi; Imai, Enyu; Yokota, Naoto; Kobayashi, Kazuo; Kashihara, Naoki

发表日期：2026

文献求助收藏

Lean body mass index and hypertension risk in men: a nationwide epidemiological cohort study

男性瘦体重指数与高血压风险：一项全国性流行病学队列研究

期刊:Hypertension Research

影响因子:4.6

doi:10.1038/s41440-025-02447-x

Azegami, Tatsuhiko; Kaneko, Hidehiro; Okada, Akira; Suzuki, Yuta; Aoyama, Kazuki; Fujiu, Katsuhito; Takeda, Norifumi; Morita, Hiroyuki; Yokoo, Takashi; Nangaku, Masaomi; Node, Koichi; Takeda, Norihiko; Yasunaga, Hideo; Hayashi, Kaori

Real-world use of HIF-PH inhibitors in the Japan dialysis and practice patterns study (J-DOPPS, 2019-2022)

日本透析和实践模式研究（J-DOPPS，2019-2022）中 HIF-PH 抑制剂的实际应用

期刊:BMC Nephrology

影响因子:2.4

doi:10.1186/s12882-026-04831-2

Eriguchi, Masahiro; Tsuruya, Kazuhiko; Noma, Hisashi; Onishi, Yoshihiro; Inuzuka, Masami; Harada, Kenji; Nangaku, Masaomi

发表日期：2026

文献求助收藏

Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors

在开始使用促红细胞生成剂或缺氧诱导因子脯氨酰羟化酶抑制剂时，应坚持监测铁指标。

期刊:Clinical and Experimental Nephrology

影响因子:1.7

doi:10.1007/s10157-025-02761-1

Miyamoto, Yoshihisa; Okada, Akira; Sasabuchi, Yusuke; Nangaku, Masaomi; Yasunaga, Hideo

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

SGLT2抑制剂与老年糖尿病肾病患者死亡率：一项目标试验模拟研究

期刊:Diabetes Obesity & Metabolism

影响因子:

doi:10.1111/dom.70502

Azegami, Tatsuhiko; Kaneko, Hidehiro; Okada, Akira; Suzuki, Yuta; Ko, Toshiyuki; Aoyama, Kazuki; Nakayama, Takashin; Kimura, Yuya; Fujiu, Katsuhiko; Takeda, Norifumi; Morita, Hiroyuki; Yokoo, Takashi; Node, Koichi; Nangaku, Masaomi; Takeda, Norihiko; Yasunaga, Hideo; Hayashi, Kaori

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)

非奈利酮对 2 型糖尿病合并慢性肾病患者动脉僵硬和心肾生物标志物的影响：一项随机安慰剂对照机制试验（FIVE-STAR）

期刊:Cardiovascular Diabetology

影响因子:10.6

doi:10.1186/s12933-025-03014-x

Tanaka, Atsushi; Vaduganathan, Muthiah; Imai, Takumi; Okada, Yosuke; Sonoda, Satomi; Torimoto, Keiichi; Suwa, Satoru; Teragawa, Hiroki; Miyazono, Motoaki; Fukuda, Makoto; Yonezu, Keisuke; Takahashi, Naohiko; Yoshida, Yuichi; Tanaka, Kenichi; Shimabukuro, Michio; Hotta, Yuki; Moroi, Masao; Niikura, Hiroki; Kida, Keisuke; Yokota, Kenichi; Fukuda, Daiju; Tanabe, Kengo; Horiuchi, Yu; Toyoda, Shigeru; Taguchi, Isao; Yoshida, Hisako; Miyoshi, Toru; Nangaku, Masaomi; Shibata, Hirotaka; Node, Koichi

Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria

恩格列净治疗伴或不伴蛋白尿的慢性肾病患者的成本效益

期刊:Clinical Journal of the American Society of Nephrology

影响因子:7.1

doi:10.2215/CJN.0000000582

Odawara, Motoki; Nishi, Hiroshi; Kodera, Satoshi; Kondo, Masahide; Nangaku, Masaomi

发表日期：2025

文献求助收藏

Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study

根据体重指数评估SGLT2抑制剂对2型糖尿病患者肾脏结局的影响：一项全国性队列研究

期刊:European Heart Journal-Cardiovascular Pharmacotherapy

影响因子:6.1

doi:10.1093/ehjcvp/pvae094

Jimba, Takahiro; Kaneko, Hidehiro; Suzuki, Yuta; Okada, Akira; Azegami, Tatsuhiko; Ko, Toshiyuki; Fujiu, Katsuhito; Morita, Hiroyuki; Takeda, Norifumi; Hayashi, Kaori; Yokoo, Takashi; Node, Koichi; Komuro, Issei; Yasunaga, Hideo; Nangaku, Masaomi; Takeda, Norihiko

Pyruvate Dehydrogenase and Cellular Metabolism in Calcineurin Inhibitor-Induced Kidney Fibrosis

钙调磷酸酶抑制剂诱导的肾纤维化中丙酮酸脱氢酶和细胞代谢

Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database

按年龄、肾功能和体重指数分层的抗糖尿病药物使用趋势演变：来自全国索赔数据库的启示

Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD Study)

日本肾脏协会-培马贝特干预治疗慢性肾脏病患者研究（JKAPI-CKD 研究）的设计

Lean body mass index and hypertension risk in men: a nationwide epidemiological cohort study

男性瘦体重指数与高血压风险：一项全国性流行病学队列研究

Real-world use of HIF-PH inhibitors in the Japan dialysis and practice patterns study (J-DOPPS, 2019-2022)

日本透析和实践模式研究（J-DOPPS，2019-2022）中 HIF-PH 抑制剂的实际应用

Adherence to monitoring iron indices at the initiation of erythropoiesis-stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors

在开始使用促红细胞生成剂或缺氧诱导因子脯氨酰羟化酶抑制剂时，应坚持监测铁指标。

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

SGLT2抑制剂与老年糖尿病肾病患者死亡率：一项目标试验模拟研究

Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR)

非奈利酮对 2 型糖尿病合并慢性肾病患者动脉僵硬和心肾生物标志物的影响：一项随机安慰剂对照机制试验（FIVE-STAR）

Cost-Effectiveness of Empagliflozin in CKD with or without Albuminuria

恩格列净治疗伴或不伴蛋白尿的慢性肾病患者的成本效益

Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study

根据体重指数评估SGLT2抑制剂对2型糖尿病患者肾脏结局的影响：一项全国性队列研究